PL3497104T3 - Postacie w stanie stałym soli ditosylanowej lumateperonu - Google Patents

Postacie w stanie stałym soli ditosylanowej lumateperonu

Info

Publication number
PL3497104T3
PL3497104T3 PL17754571T PL17754571T PL3497104T3 PL 3497104 T3 PL3497104 T3 PL 3497104T3 PL 17754571 T PL17754571 T PL 17754571T PL 17754571 T PL17754571 T PL 17754571T PL 3497104 T3 PL3497104 T3 PL 3497104T3
Authority
PL
Poland
Prior art keywords
lumateperone
solid state
state forms
ditosylate salt
ditosylate
Prior art date
Application number
PL17754571T
Other languages
English (en)
Inventor
Ariel Mittelman
Ido FUCHS
Sharona SHACHANTOV
Doron RUDIK
Rotem SELLA-EREZ
Original Assignee
Teva Pharmaceuticals International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59656224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3497104(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals International Gmbh filed Critical Teva Pharmaceuticals International Gmbh
Publication of PL3497104T3 publication Critical patent/PL3497104T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17754571T 2016-08-09 2017-08-08 Postacie w stanie stałym soli ditosylanowej lumateperonu PL3497104T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662372553P 2016-08-09 2016-08-09
US201662382479P 2016-09-01 2016-09-01
US201662382977P 2016-09-02 2016-09-02
US201662400358P 2016-09-27 2016-09-27
US201762486554P 2017-04-18 2017-04-18
EP17754571.2A EP3497104B1 (en) 2016-08-09 2017-08-08 Solid state forms of lumateperone ditosylate salt
PCT/US2017/045877 WO2018031535A1 (en) 2016-08-09 2017-08-08 Solid state forms of lumateperone ditosylate salt

Publications (1)

Publication Number Publication Date
PL3497104T3 true PL3497104T3 (pl) 2022-02-21

Family

ID=59656224

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17754571T PL3497104T3 (pl) 2016-08-09 2017-08-08 Postacie w stanie stałym soli ditosylanowej lumateperonu

Country Status (9)

Country Link
US (3) US11332469B2 (pl)
EP (2) EP4001281A1 (pl)
ES (1) ES2901375T3 (pl)
HR (1) HRP20211666T1 (pl)
HU (1) HUE057055T2 (pl)
IL (1) IL264521A (pl)
PL (1) PL3497104T3 (pl)
SI (1) SI3497104T1 (pl)
WO (1) WO2018031535A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2727815T3 (es) 2012-04-14 2019-10-18 Intra Cellular Therapies Inc Tratamiento del TEPT y de trastornos del control de impulsos
HUE057055T2 (hu) * 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
EP3687535B1 (en) 2017-09-26 2025-09-24 Intra-Cellular Therapies, Inc. Crystalline hydrochloride salt of lumateperone
US11655251B2 (en) 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
AU2019280850C1 (en) 2018-06-06 2025-02-13 Intra-Cellular Therapies, Inc. Novel salts and crystals
ES3028377T3 (en) 2018-06-08 2025-06-19 Intra Cellular Therapies Inc Fused gamma-carbolines for acute treatment of anxiety or depression
CA3106447A1 (en) * 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CN112584838A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
AU2019398451B2 (en) * 2018-12-14 2024-12-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3898221A4 (en) 2018-12-17 2022-09-14 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
EP3897621A4 (en) 2018-12-21 2022-09-07 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
JP7673040B2 (ja) * 2019-07-07 2025-05-08 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
US11753419B2 (en) 2019-12-11 2023-09-12 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
WO2022195500A1 (en) * 2021-03-16 2022-09-22 Ami Organics Ltd. A process for the preparation of lumateperone tosylate intermediate
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
JP2025525812A (ja) * 2022-07-30 2025-08-07 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規な塩および結晶
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods
CN118566395B (zh) * 2024-08-02 2024-10-25 则正(济南)生物科技有限公司 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3663294A1 (en) 2007-03-12 2020-06-10 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
SI2262505T1 (sl) 2008-03-12 2015-03-31 Intra-Cellular Therapies, Inc. Substituirana heterociklirano zliti gama-karbolinska trdna snov
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
HUE057055T2 (hu) * 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
US11655251B2 (en) 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
AU2019280850C1 (en) 2018-06-06 2025-02-13 Intra-Cellular Therapies, Inc. Novel salts and crystals
CA3106447A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
CN112584838A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof

Also Published As

Publication number Publication date
US20220127268A1 (en) 2022-04-28
US11760757B2 (en) 2023-09-19
ES2901375T3 (es) 2022-03-22
US11332469B2 (en) 2022-05-17
US20230382914A1 (en) 2023-11-30
IL264521A (en) 2019-05-30
HUE057055T2 (hu) 2022-04-28
EP4001281A1 (en) 2022-05-25
HRP20211666T1 (hr) 2022-02-18
EP3497104A1 (en) 2019-06-19
SI3497104T1 (sl) 2021-12-31
EP3497104B1 (en) 2021-10-06
WO2018031535A1 (en) 2018-02-15
US20190211015A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
IL264521A (en) Solid forms of lometaferon ditosylate
IL257026A (en) Solid state forms of eluxadoline
SG11201706729SA (en) Derivatives of sobetirome
PT3466934T (pt) Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
SI3154526T1 (sl) Trdne oblike sofosbuvira
SMT202100551T1 (it) Derivati di sobetirome
IL265628A (en) Solid state forms of valbenazine
IL274627A (en) Solid forms of valbenazine
IL263853A (en) Solid state forms of palbociclib dimesylate
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
LT3430004T (lt) Nilotinibo druskų kietosios būsenos formos
GB201701939D0 (en) Salt
IL263673A (en) Solid state forms of spiro-oxindole compounds
ZA201803035B (en) Biomarker of polycystic kidney disease and uses thereof
IL272670A (en) Preparation of micro-electrodes
IL246569A0 (en) Solid forms of tenofovir
GB201602857D0 (en) Connection of rotatable parts
GB201600964D0 (en) Determination of vehicle capabilities
IL254666A0 (en) Crystalline forms of Aldecalcitol
HUP1500506A2 (en) Salts of palbociclib
GB201721386D0 (en) Chrondogy of time-wave
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201519795D0 (en) Construction of surfaces